154 related articles for article (PubMed ID: 38320184)
1. New Targeted Therapy Combination Holds Promise to Untangle Hairy Cell Leukemia.
Soong D; Taylor J
NEJM Evid; 2023 Oct; 2(10):EVIDe2300173. PubMed ID: 38320184
[TBL] [Abstract][Full Text] [Related]
2. BRAF in the cross-hairs.
Geyer MB; Abdel-Wahab O; Tallman MS
Expert Rev Hematol; 2019 Mar; 12(3):183-193. PubMed ID: 30782032
[TBL] [Abstract][Full Text] [Related]
3. BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity.
Pettirossi V; Santi A; Imperi E; Russo G; Pucciarini A; Bigerna B; Schiavoni G; Fortini E; Spanhol-Rosseto A; Sportoletti P; Mannucci R; Martelli MP; Klein-Hitpass L; Falini B; Tiacci E
Blood; 2015 Feb; 125(8):1207-16. PubMed ID: 25480661
[TBL] [Abstract][Full Text] [Related]
4. Inhibitor of BRAF
Smirnova SY; Al-Radi LS; Moiseeva TN; Gemdzhian EG; Yakutik IA; Julhakyan HL; Novikov VA; Galstyan GM; Sudarikov AB
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):427-430. PubMed ID: 33811006
[TBL] [Abstract][Full Text] [Related]
5. BRAF inhibitor therapy in HCL.
Dietrich S; Zenz T
Best Pract Res Clin Haematol; 2015 Dec; 28(4):246-52. PubMed ID: 26614903
[TBL] [Abstract][Full Text] [Related]
6. BRAF mutations in hairy-cell leukemia.
Tiacci E; Trifonov V; Schiavoni G; Holmes A; Kern W; Martelli MP; Pucciarini A; Bigerna B; Pacini R; Wells VA; Sportoletti P; Pettirossi V; Mannucci R; Elliott O; Liso A; Ambrosetti A; Pulsoni A; Forconi F; Trentin L; Semenzato G; Inghirami G; Capponi M; Di Raimondo F; Patti C; Arcaini L; Musto P; Pileri S; Haferlach C; Schnittger S; Pizzolo G; Foà R; Farinelli L; Haferlach T; Pasqualucci L; Rabadan R; Falini B
N Engl J Med; 2011 Jun; 364(24):2305-15. PubMed ID: 21663470
[TBL] [Abstract][Full Text] [Related]
7. Long term follow-up of refractory/relapsed hairy cell leukaemia patients treated with low-dose vemurafenib between 2013 and 2022 at the Department of Internal Medicine and Oncology, Semmelweis University.
Ferenczi K; Nagy ZF; Istenes I; Eid H; Bödör C; Timár B; Demeter J
Pathol Oncol Res; 2023; 29():1611378. PubMed ID: 38025907
[No Abstract] [Full Text] [Related]
8. Update on the biology and treatment options for hairy cell leukemia.
Jain P; Pemmaraju N; Ravandi F
Curr Treat Options Oncol; 2014 Jun; 15(2):187-209. PubMed ID: 24652320
[TBL] [Abstract][Full Text] [Related]
9. Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib.
Blachly JS; Lozanski G; Lucas DM; Grever MR; Kendra K; Andritsos LA
J Natl Compr Canc Netw; 2015 Jan; 13(1):9-13; quiz 13. PubMed ID: 25583765
[TBL] [Abstract][Full Text] [Related]
10. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia.
Tiacci E; Schiavoni G; Martelli MP; Boveri E; Pacini R; Tabarrini A; Zibellini S; Santi A; Pettirossi V; Fortini E; Ascani S; Arcaini L; Inghirami G; Paulli M; Falini B
Haematologica; 2013 Apr; 98(4):635-9. PubMed ID: 23349307
[TBL] [Abstract][Full Text] [Related]
11. BRAF inhibition in hairy cell leukemia with low-dose vemurafenib.
Dietrich S; Pircher A; Endris V; Peyrade F; Wendtner CM; Follows GA; Hüllein J; Jethwa A; Ellert E; Walther T; Liu X; Dyer MJ; Elter T; Brummer T; Zeiser R; Hermann M; Herold M; Weichert W; Dearden C; Haferlach T; Seiffert M; Hallek M; von Kalle C; Ho AD; Gaehler A; Andrulis M; Steurer M; Zenz T
Blood; 2016 Jun; 127(23):2847-55. PubMed ID: 26941398
[TBL] [Abstract][Full Text] [Related]
12. Single agent vemurafenib or rituximab-vemurafenib combination for the treatment of relapsed/refractory hairy cell leukemia, a multicenter experience.
Yiğit Kaya S; Mutlu YG; Malkan ÜY; Mehtap Ö; Keklik Karadağ F; Korkmaz G; Elverdi T; Saydam G; Özet G; Ar MC; Melek E; Maral S; Kaynar L; Sevindik ÖG
Leuk Res; 2024 May; 140():107495. PubMed ID: 38599153
[TBL] [Abstract][Full Text] [Related]
13. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
14. BRAF V600E mutation in hairy cell leukemia: from bench to bedside.
Falini B; Martelli MP; Tiacci E
Blood; 2016 Oct; 128(15):1918-1927. PubMed ID: 27554081
[TBL] [Abstract][Full Text] [Related]
15. Hairy cell leukemia: a 'hair-raising' update.
Topp ZZ; Saven A
Expert Rev Hematol; 2014 Oct; 7(5):659-69. PubMed ID: 25148599
[TBL] [Abstract][Full Text] [Related]
16. How I treat refractory/relapsed hairy cell leukemia with BRAF inhibitors.
Falini B; De Carolis L; Tiacci E
Blood; 2022 Apr; 139(15):2294-2305. PubMed ID: 35143639
[TBL] [Abstract][Full Text] [Related]
17. Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia.
Tiacci E; Park JH; De Carolis L; Chung SS; Broccoli A; Scott S; Zaja F; Devlin S; Pulsoni A; Chung YR; Cimminiello M; Kim E; Rossi D; Stone RM; Motta G; Saven A; Varettoni M; Altman JK; Anastasia A; Grever MR; Ambrosetti A; Rai KR; Fraticelli V; Lacouture ME; Carella AM; Levine RL; Leoni P; Rambaldi A; Falzetti F; Ascani S; Capponi M; Martelli MP; Park CY; Pileri SA; Rosen N; Foà R; Berger MF; Zinzani PL; Abdel-Wahab O; Falini B; Tallman MS
N Engl J Med; 2015 Oct; 373(18):1733-47. PubMed ID: 26352686
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis using a BRAF V600E mutation specific antibody is highly sensitive and specific for the diagnosis of hairy cell leukemia.
Wang XJ; Kim A; Li S
Int J Clin Exp Pathol; 2014; 7(7):4323-8. PubMed ID: 25120816
[TBL] [Abstract][Full Text] [Related]
19. Hairy cell leukemia: Past, present and future.
Getta BM; Park JH; Tallman MS
Best Pract Res Clin Haematol; 2015 Dec; 28(4):269-72. PubMed ID: 26614906
[TBL] [Abstract][Full Text] [Related]
20. Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations.
Durham BH; Getta B; Dietrich S; Taylor J; Won H; Bogenberger JM; Scott S; Kim E; Chung YR; Chung SS; Hüllein J; Walther T; Wang L; Lu SX; Oakes CC; Tibes R; Haferlach T; Taylor BS; Tallman MS; Berger MF; Park JH; Zenz T; Abdel-Wahab O
Blood; 2017 Oct; 130(14):1644-1648. PubMed ID: 28801450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
